318 related articles for article (PubMed ID: 21320060)
1. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
[TBL] [Abstract][Full Text] [Related]
2. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
3. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
[TBL] [Abstract][Full Text] [Related]
4. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
[TBL] [Abstract][Full Text] [Related]
5. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
[TBL] [Abstract][Full Text] [Related]
7. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
[TBL] [Abstract][Full Text] [Related]
8. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
[TBL] [Abstract][Full Text] [Related]
9. The protein-protein interactions as a target in medicinal chemistry and drug discovery.
Mustata G
Curr Top Med Chem; 2011; 11(3):247. PubMed ID: 21320055
[No Abstract] [Full Text] [Related]
10. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
Brunden KR; Trojanowski JQ; Smith AB; Lee VM; Ballatore C
Bioorg Med Chem; 2014 Sep; 22(18):5040-9. PubMed ID: 24433963
[TBL] [Abstract][Full Text] [Related]
11. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.
Barten DM; Fanara P; Andorfer C; Hoque N; Wong PY; Husted KH; Cadelina GW; Decarr LB; Yang L; Liu V; Fessler C; Protassio J; Riff T; Turner H; Janus CG; Sankaranarayanan S; Polson C; Meredith JE; Gray G; Hanna A; Olson RE; Kim SH; Vite GD; Lee FY; Albright CF
J Neurosci; 2012 May; 32(21):7137-45. PubMed ID: 22623658
[TBL] [Abstract][Full Text] [Related]
12. Tau and Axonal Transport Misregulation in Tauopathies.
Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
15. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
Venkatramani A; Panda D
Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
[TBL] [Abstract][Full Text] [Related]
16. Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.
Pickhardt M; Neumann T; Schwizer D; Callaway K; Vendruscolo M; Schenk D; St George-Hyslop P; Mandelkow EM; Dobson CM; McConlogue L; Mandelkow E; Tóth G
Curr Alzheimer Res; 2015; 12(9):814-28. PubMed ID: 26510979
[TBL] [Abstract][Full Text] [Related]
17. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
18. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
20. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
Gallo JM; Noble W; Martin TR
Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]